Effects of secukinumab on serum adipocytokines: preliminary data by Fassio, Angelo et al.
Reumatismo 3/2017 105
ORIGINAL
PAPERReumatismo, 2017; 69 (3): 105-110
Effects of secukinumab on serum 
adipocytokines: preliminary data
A. Fassio1, D. Gatti1, P. Gisondi2, G. Girolomoni2, O. Viapiana1, A. Giollo1, 
M. Zamboni3, M. Rossini1, L. Idolazzi1
1Unit of Rheumatology, University of Verona, Italy; 2Unit of Dermatology, University of Verona, Italy; 
3Unit of Geriatrics, University of Verona, Italy
SUMMARY
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects joints, connective tissues and the axial 
skeleton. Metabolic syndrome is an independent risk factor for psoriasis (Pso) development and is associated 
with more severe forms of Pso. Adipocytokines are secreted by white adipose tissue and are thought to link 
obesity with the development of metabolic and cardiovascular diseases. Secukinumab is a new monoclonal 
antibody with a different mechanism of action. This antibody selectively binds to and neutralizes interleukin-17 
(IL-17) and it has shown efficacy in the treatment of PsA. The aim of this study was to evaluate the possible 
interferences of secukinumab on different adipocytokines.
We enrolled 28 patients with PsA, classified with the CASPAR criteria. Serum samples were stored at baseline 
and then at the first, the third and the sixth month of therapy. Resistin, chemerin, adiponectin and C-reactive 
protein (CRP) were dosed.
When tested globally, none of the adipokine tested showed any statistically significant variation. However, 
when the male group was tested, both resistin and chemerin at M6 showed a significant decrease from baseline. 
CRP did not show any variation at any time point.
Our study demonstrated that treatment with secukinumab has little influence on the levels of adipokines tested 
within the first six months of treatment even though it might exert different influence between males and fe-
males from a metabolic perspective. Further studies with greater numbers of patients are needed to determine 
whether these preliminary results have clinical relevance.
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n	 INTRODUCTION
Psoriasis (Pso) is a common chronic in-flammatory disease involving the skin 
that can be associated with several comor-
bidities, one of which is psoriatic arthritis 
(PsA) (1). Psoriatic arthritis is a chronic, 
systemic inflammatory disease affecting 
peripheral joints, connective tissues, and 
the axial skeleton and is associated with 
psoriasis of the skin and nails (1).
Patients with Pso and PsA share obesity 
(and related complications) and cardio-
vascular (CV) diseases. Chronic inflam-
mation in Pso and PsA can partially ex-
plain the development of atherosclerosis 
and CV diseases, but also the concomi-
tant alterations in the glucose metabolism 
(diabetes and insulin resistance) and lipids 
(dyslipidaemia) enhance this risk (2).
Systemic inflammation induced by obesity 
and metabolic syndrome could exacerbate 
local inflammation, worsening both Pso 
and PsA (3). Indeed, increasing evidence 
is suggesting that metabolic syndrome is 
an independent risk factor for Pso devel-
opment and is associated with more severe 
forms of Pso (3).
Nowadays, adipose tissue is considered 
as an active endocrine and immune or-
gan, producing various cytokines, named 
adipocytokines, and they link together in-
flammation and metabolic disorders (4). 
Adipocytokines, in cooperation with mac-
rophages and T cells, induce and modulate 
adipose tissue inflammation, contribute to 
the pathogenesis of metabolic syndrome 
and enhance local inflammation at skin and 
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dance with the ethics principles of the Dec-
laration of Helsinki and was approved by 
the local ethics committee; all the partici-
pants provided written informed consent 
for their participation in the study.
Subjects
The criteria for inclusion were: stable treat-
ment with parenteral methotrexate in the 
last three months (ranging from 10 mg to 
15 mg weekly), time since the diagnosis ≤3 
years.
The exclusion criteria for the samples of 
PsA patients were: systemic inflamma-
tory diseases, active infections, neoplasms, 
renal, liver, endocrine or metabolic bone 
diseases, pregnancy and current use of bio-
logical treatment and corticosteroids. All 
patients received Vitamin D3 supplementa-
tion during the course of the study (7500 
Ui/week). 
Metabolic syndrome (MS) was diagnosed 
in 12 out of 28 patients in the sample (43%), 
with no differences in its prevalence be-
tween men (4/10, 40%) and women (8/18, 
44%). The diagnosis of MS was based on 
the current criteria (15). These 12 patients 
were in treatment either for hypertension, 
for their dyslipidemia, or for type 2 diabe-
tes, but their treatment did not change dur-
ing the period of follow up.
The 28 joints Disease Activity Score 
(DAS28) was recorded at every time point. 
Serum samples of the patients treated with 
secukinumab (with doses ranging from 75 
to 150 mg every month) were stored dur-
ing the treatment at baseline and then at 
the first, the third and the sixth month of 
therapy.
Biochemical assessment
Blood samples were collected and stored at 
−50°C and later tested for adipokines. All 
the samples were processed in the labora-
tory of the Rheumatology Unit of Azienda 
Ospedaliera Universitaria Integrata di Ve-
rona. An ELISA assay was used for the 
quantitative determination of C-reactive 
protein (CRP) (CRP HS ELISA, DRG 
Instruments GmbH, Germany), with an 
inter-assay CV <4.1% and an intra-assay 
CV <7.5%. Serum concentration of human 
articular level. Adipocytokines are secreted 
by white adipose tissue and are thought to 
link obesity with the development of meta-
bolic diseases (5).
Many adipocytokines, including adiponec-
tin, resistin and chemerin contribute to the 
development of insulin resistance and low-
grade inflammation (6, 7). Adiponectin and 
resistin exert opposite effects on glucose 
metabolism: while adiponectin sensitises 
tissues to insulin, the latter promotes devel-
opment of insulin resistance (8). Chemerin 
is also an adipocytokine implicated in the 
immune response with both pro and anti-
inflammatory properties (6). All these cy-
tokines not only play roles in metabolism 
but also are involved in development of 
chronic inflammation (9).
Inhibitors of tumor necrosis factor (TNFi) 
have significantly improved outcomes 
among patients with psoriatic arthritis 
and have been available for the treatment 
of PsA for many years now (10). On the 
contrary, secukinumab is a new monoclo-
nal antibody with a different mechanism of 
action. This antibody selectively binds to 
and neutralizes interleukin-17 (IL-17) and 
it has shown efficacy in the treatment of 
psoriasis, ankylosing spondylitis and pso-
riatic arthritis (11). IL-17 is an important 
cytokine involved in the pathogenesis of 
psoriatic arthritis. Increased levels of cells 
that produce IL-17 are found in the circu-
lation, joints, and skin plaques of patients 
with psoriatic arthritis (12).
Finally, some data seem to suggest that 
adipocytokines could also act by interfer-
ing with IL-17 axis (3, 13, 14). For these 
reasons we decided to evaluate the possible 
interferences of secukinumab on different 
adipocytokines.
n	 MATERIALS AND METHODS
Study design
This is a prospective study conducted in 
our outpatient clinic in the Rheumatology 
Division of Azienda Ospedaliera Universi-
taria Integrata di Verona. The study sample 
included 28 patients with PsA classified 
with the CASPAR criteria, recruited at our 
center. The study was conducted in accor-
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resistin, chemerin and adiponectin were 
dosed using commercial ELISA kits (Me-
diagnost, Reutlingen, Germany). Resistin 
intra-assay variation was <5% and inter-as-
say variation was <6.8% with a sensitivity 
of 0.006 ng/mL. The inter- and intra-assay 
CV of chemerin were <5.16 and <2.17% 
respectively while the inter-assay and in-
tra-assay CV of adiponectin were <6.7% 
and <4.7% respectively. The anthropomet-
ric values and adipokines’ concentrations 
are shown in Table I.
Statistical analysis
All statistical analyses were performed 
per protocol by SPSS software, Version 22 
(SPSS, Inc., Chicago, IL, USA). The dif-
ferences between the values of the mark-
ers at month 1, 3 and 6 vs baseline were 
analyzed by one-sample t test. Correlations 
were calculated using linear regression. 
Two sided p values of 0.05 or less were 
considered significant. Data are presented 
as mean ± SD.
n	 RESULTS
The demographics of the sample and the 
values of the dosed markers at baseline are 
shown in Table I. The percentage changes 
from baseline to month 1 (M1), month 3 
(M3) and month 6 (M6) of PCR, resistin, 
adiponectin and chemerin are shown in Ta-
ble II as mean ± standard deviation (SD). 
The weight of the patients, the levels of 
CRP and the values of DAS28 did not show 
a significant change at any point (data not 
shown).
We transformed CPR values into LnCRP 
to obtain a normal distribution for this pa-
rameter.
Table I - Demographics of the sample and values 
of the dosed markers at baseline (units in brackets).
Mean±SD
Age 57.39±9.94
Weight (kg) 77.67±14.9
Height (cm) 163.21±8.24
BMI 29.11±5.3
M/F 10/18
CRP mg/L 11.9±22.51
Chemerin ng/mL 204.9±37.79
Adiponectin ug/mL 15.9±9.71
Resistin ng/mL 7.84±3.179
Table II - Percentage variation (± SD) from baseline to the first, third and sixth month of observation of the dosed markers. DAS28 (± 
SD) is reported as absolute value.
Baseline to month 1 Baseline to month 3 Baseline to month 6
Resistin variation % 2.75±17.45 –4.91±19.44 –1.19±21.85
Adiponectin variation % –3.61±15.36 1.33±26.31 –1.65±21.73
Chemerin variation % –0.81±12.78 –3.52±14.82 –4.50±14.79
DAS28 3.78±1.21 3.57±1.58 3.41±1.55
Figure 1 - Correlation between all the values of lnCRP vs resistin, adiponectin and chemerin. All p<0.05.
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A positive correlation was found between 
the overall values of CRP and both resis-
tin (p<0.001, R2=0.326) and chemerin 
(p<0.001, R2=0.251) and a weak nega-
tive correlation for adiponectin (p<0.046, 
R2=0.036) (Figure 1). 
None of the adipokines-tested patients 
demonstrated a significant fluctuation 
when the values were tested globally, but 
when the values of the males were tested 
separately, both resistin and chemerin at 
M6 showed a significant decrease from 
baseline, while adiponectin and CRP still 
did not exhibit any significant variation 
(Table III). 
No significant change was found when the 
females only were tested. No significant 
differences at baseline were observed con-
cerning the levels of the tested adipokines 
between males and females.
n	 DISCUSSION
Our data confirm both the already known 
relationship between proinflammatory adi-
pokines such as resistin and chemerin and 
CRP (16-18), and also the expected nega-
tive correlation between adiponectin and 
CRP, already well described in previous 
studies both in non-arthritic patients (16) 
and in PsA patients (19). 
The changes of adipokines levels during 
treatment with TNFi in chronic inflam-
matory conditions has already been stud-
ied. When the changes in proinflammatory 
adipokines (such as resistin and chemerin) 
were considered, the results were not uni-
vocal (20-22). Also for adiponectin (a cyto-
kine with antinflammatory action), the ef-
fects of TNFi treatment was not consistent 
(23-25).
This is the first time that adipokines have 
been evaluated during the IL-17 blockade. 
These are preliminary data throughout the 
first six months of therapy. 
During this time period, the levels of 
adipokines showed overall no significant 
variation. Furthermore, when we consid-
ered the male subgroup, we found a rel-
evant and significant decrease in the levels 
of both chemerin (about -12%) and resis-
tin (about -24%). 
These are pro-inflammatory molecules 
and this remark could be of clinical rele-
vance in patients with a chronic inflamma-
tory disease such as PsA, despite no sig-
nificant changes having been documented 
on CRP. Indeed, we should remember that 
in PsA, CRP alone is not always correlat-
ed with disease activity (26). Finally, the 
reduction of chemerin and resistin might 
exert positive effects also towards the 
metabolic profile of the patients. A valid 
explanation, possibly helpful in explain-
ing why this finding is being observed 
only in the male subgroup, might be the 
lack of statistical power due to the limited 
number of subjects involved in this study 
(10 males and 18 females respectively). 
Anyway, we cannot rule out the possibil-
ity that a different gender-based response 
to the treatment may be present. Indeed, 
the correlation was lost not only when we 
considered the female subgroup but also 
when the whole study population was ex-
amined. Further studies with higher num-
ber of patients and longer times of obser-
vation are needed to define this question 
better.
In addition, in a murine model (27), it has 
been demonstrated that adiponectin may 
promote Th-17 cell differentiation through 
the upregulation of the expression of ret-
inoid-related orphan nuclear receptor-γt 
(ROR-γt), IL-22 and IL-23. Thus, in future 
Table III - Percentage variation in males and in females, from baseline to the 
sixth month.
Males N=10
Baseline to month 6 p
Weight % variation 0.23±0.35 Ns
CRP % variation –16.53±87.65 Ns
Resistin % variation –12.45±13.39 0.016
Adiponectin % variation –3.00±21.28 Ns
Chemerin % variation –23.81±28.76 0.028
Females N=18
Weight % variation 0.89±1.2 Ns
CRP % variation 81.05±236.50 Ns
Resistin % variation 5.06±23.34 Ns
Adiponectin % variation –0.90±22.60 Ns
Chemerin % variation –0.60±14.70 Ns
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studies, the evaluation of IL-17 concentra-
tions along with adipokines in patients af-
fected by PsA (and the search for any mod-
ifications during IL-17 blockade) might 
provide new important insights on the pos-
sible role of anti IL-17 drugs, also for the 
treatment of the metabolic consequences of 
the psoriatic disease.
n	 CONCLUSIONS
Our study has several limitations. First, 
there is no control group and the sample 
size is limited. Second, the time extent of 
the observation is limited and, possibly, 
too short to document significant varia-
tions on some of the markers tested. Third, 
the traditional metabolic lab tests were not 
evaluated (i.e., blood glucose, HbA1c, lipid 
profile). 
Our intent was purely to investigate 
whether secukinumab has any acute ef-
fect on weight and/or adipokines. These 
preliminary data may bring new insights 
for further studies concerning the possibil-
ity of specific and unexpected effects that 
secukinumab might have towards the adi-
pokines profile in males and females.
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